Galectin-3 Inhibition in COVID-19

Kiran Reddy^{1

2}, Alistair Nichol^{3

4

5

6}, Daniel F McAuley^{1

2}

Affiliations

¹ School of Medicine, Dentistry and Biomedical Sciences Queen's University Belfast Belfast, Northern Ireland.
² Regional Intensive Care Unit Royal Victoria Hospital Belfast, Northern Ireland.
³ Australian and New Zealand Intensive Care Research Centre Monash University Melbourne, Victoria, Australia.
⁴ Department of Intensive Care Alfred Hospital Melbourne, Victoria, Australia.
⁵ Department of Anaesthesia and Intensive Care Medicine St. Vincent's University Hospital Dublin, Ireland.
⁶ School of Medicine and Medical Sciences University College Dublin Dublin, Ireland.

Editorial

Kiran Reddy et al. Am J Respir Crit Care Med. 2023.

. 2023 Jan 15;207(2):118-120.

doi: 10.1164/rccm.202209-1758ED.

Kiran Reddy^{1

2}, Alistair Nichol^{3

4

5

6}, Daniel F McAuley^{1

2}

¹ School of Medicine, Dentistry and Biomedical Sciences Queen's University Belfast Belfast, Northern Ireland.
² Regional Intensive Care Unit Royal Victoria Hospital Belfast, Northern Ireland.
³ Australian and New Zealand Intensive Care Research Centre Monash University Melbourne, Victoria, Australia.
⁴ Department of Intensive Care Alfred Hospital Melbourne, Victoria, Australia.
⁵ Department of Anaesthesia and Intensive Care Medicine St. Vincent's University Hospital Dublin, Ireland.
⁶ School of Medicine and Medical Sciences University College Dublin Dublin, Ireland.

No abstract available

Comment on

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE).
Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O'Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar-Hari M, Hirani N, Sethi T, Dhaliwal K. Gaughan EE, et al. Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149. doi: 10.1164/rccm.202203-0477OC. Am J Respir Crit Care Med. 2023. PMID: 35972987 Free PMC article. Clinical Trial.

1. Thiemann S, Baum LG. Galectins and immune responses—just how do they do those things they do? Annu Rev Immunol . 2016;34:243–264. - PubMed
1. Díaz-Alvarez L, Ortega E. The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens. Mediators Inflamm . 2017;2017:9247574. - PMC - PubMed
1. Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, Teale JM, et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One . 2013;8:e59616. - PMC - PubMed
1. Xu Z, Li X, Huang Y, Mao P, Wu S, Yang B, et al. The predictive value of plasma galectin-3 for ARDS severity and clinical outcome. Shock . 2017;47:331–336. - PubMed
1. Cervantes-Alvarez E, la Rosa NL, la Mora MS, Valdez-Sandoval P, Palacios-Jimenez M, Rodriguez-Alvarez F, et al. Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci Rep . 2022;12:1856. - PMC - PubMed